Diabetes and Schizophrenia

Česká verze

Authors: L. Ustohal1ihash2 ^{,2 ,2}
Authors place of work: CEITEC MU, Brno ¹; Psychiatrická klinika LF MU a FN Brno ²
Published in the journal: Cesk Slov Neurol N 2012; 75/108(1): 111-114
Category: Novinky v léčbě

Summary

Epidemiological studies confirmed significantly higher prevalence of diabetes in patients with schizophrenia than in general population. It is supposed, that this fact is multifactorial. Some factors, such as genetic factors common for schizophrenia and diabetes, cannot be influenced, on the contrary some of them can be influenced. It is true especially for antipsychotic medication and patients‘ lifestyle. From this point of view, clozapine and olanzapine are more problematic antipsychotics, on the contrary amisulpride, aripiprazole, sertindole and ziprasidone are supposed to be safer. It is important to be informed about the risk of diabetes and other cardiometabolic complications and to regularly measure fasting glucose and other parameters, such as body mass index, fasting lipids, blood pressure and pulse during the course of schizophrenia treatment and moreover to educate patients about healthy lifestyle.

Key words:
schizophrenia –⁠ diabetes –⁠ antipsychotics

Zdroje

1. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991; 36(4): 239–245.

2. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997; 171 : 502–508.

3. Barnett AH, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Heald A et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol 2007; 21(4): 357–373.

4. Rouillon F, Sorbara F. Schizophrenia and diabetes: epidemiological data. Eur Psychiatry 2005; 20 (Suppl 4):S345–S348.

5. Nuevo R, Chatterji S, Fraguas D, Verdes E, Naidoo N, Arango C et al. Increased risk of diabetes mellitus among persons with psychotic symptoms: results from the WHO World Health Survey. J Clin Psychiatry 2011; 72(12): 1592–1599.

6. De Hert M, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Mental Health 2006; 2 : 14.

7. Coclami T, Cross M. Psychiatric co-morbidity with type 1 and type 2 diabetes mellitus. East Mediterr Health J 2011; 17(10): 777–783.

8. Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007; 116(5): 317–333.

9. Scheen AJ, De Hert MA. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab 2007; 33(3): 169–175.

10. Lin PI, Shuldiner AR. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr Res 2010; 123(2–3): 234–243.

11. Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 2010; 71(9): 1115–1124.

12. Medved V, Jovanovic N, Knapic VP. The comorbidity of diabetes mellitus and psychiatric disorders. Psychiatr Danub 2009; 21(4): 585–588.

13. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 (Suppl 1): 1–93.

14. Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 2005; 66(4): 504–514.

15. Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005; 54(3): 862–871.

16. Johnson DE, Yamazaki H, Ward KM, Schmidt AW, Lebel WS, Treadway JL et al. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets. Role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 2005; 54(5): 1552–1558.

17. Newcomer JW. Metabolic syndrome and mental illness. Am J Manag Care 2007; 13 (Suppl): S170–S177.

18. De Hert M, Vancampfort D, Correll CU, Mercken V, Peuskens J, Sweers K et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry 2011; 199(2): 99–105.